The partners will create a secure, Rush-hosted clinical analytics platform to enable Rush researchers to analyze deidentified, longitudinal, and multimodal clinical data.
The bank gave CareDx a price target of $65 per share and BillionToOne of $120 per share, noting their strong positions in non-oncology markets and recent moves into cancer testing.
The program aims to bolster domestic biomanufacturing and supply chain capabilities and speed point-of-care therapeutics production.
A polygenic risk score provided insights into hypertrophic cardiomyopathy risk and adverse cardiovascular outcomes in individuals with or without Mendelian disease contributors.
The Dow Jones Industrial Average rose 1 percent month over month, the Nasdaq rose 4 percent, and the Nasdaq Biotech Index rose 10 percent.
NEW YORK – Heidelberg Epignostix said on Tuesday that it has inked a strategic partnership with the UK National Health Service's Genomic Medicine Service (GMS) to bring the company's epigenetic ...
With ongoing reagent challenges postponing its proteome-scale ambitions indefinitely, the firm has shifted the majority of its R&D resources to developing its targeted technology.
Top Five Articles Last Week: Antibody Image Manipulation, Guardant Health to Pay $245M Damages, More
Last week, GenomeWeb’s readers were most interested in learning about a new report suggesting manipulation of antibody validation images is widespread among providers.
NEW YORK – A jury in the US District Court for the District of Delaware found that Parse Biosciences, a subsidiary of Qiagen, willfully infringed three patents belonging to Scale Biosciences, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results